title: Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL.
abstract: The presence of chromosomal gains other than trisomy 12 in chronic lymphocytic leukaemia (CLL) is unusual. However, some patients may show gains on several chromosomes simultaneously suggesting a hyperdiploid karyotype.
  
  
  OBJECTIVE
  The objective of this study was to analyse by FISH the frequency and prognostic impact of hyperdiploidy in CLL.
  
  
  METHODS
  A review of 1359 consecutive cases diagnosed with CLL referred for FISH analysis to a unique institution was carried out. Hyperdiploidy was considered when a gain of at least three of the five FISH probes used was observed.
  
  
  RESULTS
  Seven cases (0.51%) with hyperdiploidy were found, confirming that it is a rare event in this disease. Although most patients presented with early Binet stages at diagnosis, six of seven (86%) shortly progressed. The median of time to the first therapy (TTFT) and overall survival (OS) for the patients with hyperdiploidy were short (1.4 months and 20 months, respectively). Moreover, comparing them with a control group of patients (non-hyperdiploid) with completed follow-up data, TTFT and OS of the patients with hyperdiploidy were significantly shorter than the control group.
  
  
  CONCLUSIONS
  The presence of hyperdiploidy is uncommon and probably associated with poor prognostic markers in CLL.
authors.affiliation: Servicio de Hematología, Hospital Universitario Infanta Leonor, Madrid, Spain.|Departamento de Medicina, Universidad Complutense, Madrid, Spain.
authors.forename: Isabel
authors.initials: I
authors.lastname: González-Gascón Y Marín
authors.affiliation: Servicio de Hematología, IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: Ana África
authors.initials: AÁ
authors.lastname: Martín
authors.affiliation: Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca, Salamanca, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Hernández-Sanchez
authors.affiliation: Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca, Salamanca, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Robledo
authors.affiliation: Hospital Jerez de la Frontera, Cádiz, Spain.
authors.forename: María Lourdes
authors.initials: ML
authors.lastname: Hermosín
authors.affiliation: Hospital Virgen Blanca, León, Spain.
authors.forename: Natalia
authors.initials: N
authors.lastname: de Las Heras
authors.affiliation: Hospital Miguel Servet, Zaragoza, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Lacalle
authors.affiliation: Hospital el Bierzo, Ponferrada, León, Spain.
authors.forename: Josefina
authors.initials: J
authors.lastname: Galende
authors.affiliation: Hospital Morales Meseguer, Murcia, Spain.
authors.forename: Felipe
authors.initials: F
authors.lastname: de Arriba
authors.affiliation: Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca, Salamanca, Spain.
authors.forename: Ana Eugenia
authors.initials: AE
authors.lastname: Rodríguez-Vicente
authors.affiliation: Servicio de Hematología, Hospital Universitario Infanta Leonor, Madrid, Spain.|Departamento de Medicina, Universidad Complutense, Madrid, Spain.
authors.forename: José-Ángel
authors.initials: JÁ
authors.lastname: Hernández
authors.affiliation: Servicio de Hematología, IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain.|Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca, Salamanca, Spain.
authors.forename: Jesús María
authors.initials: JM
authors.lastname: Hernández-Rivas
mesh_terms: D000368:Aged; D015415:Biomarkers; D016022:Case-Control Studies; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011123:Polyploidy; D011379:Prognosis; D012189:Retrospective Studies; D061665:Time-to-Treatment; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
chemical_list: D015415:Biomarkers; D016159:Tumor Suppressor Protein p53
keywords: chronic lymphocytic leukaemia; fluorescence in situ hybridisation; hyperdiploidy; prognosis